Expert: Professor Ravi Bhatia Director of the Stem Cell Program at the University of Alabama in Birmingham (USA)

Program:
Overview of significant biological aspects presented during the meeting, including:

• 03:44 Pre-treatment biological characteristics determining response
  
  • A single-cell Atlas identifies pretreatment features of primary imatinib resistance in CML
• 11:47 Novel approaches to targeting leukemia stem cells
  • Integrated high-throughput drug profiling and CRISPR screening identify novel pathway vulnerabilities of leukemic stem cells in CML
  • Discovery of an exceptionally potent PROTAC degrading native and mutant BCR-ABL1 oncoprotein in CML
• 21:59 Metabolic vulnerabilities in leukemia stem cells
  • Metabolic adaptation to tyrosine kinase inhibition in chronic myelogenous leukemia stem cells
  • Targeting HIF-2α for the treatment of CML by affecting LSCs metabolism and the vascular microenvironment
• 26:33 Questions and Answers

If you have any questions or comments to the speaker, please email info@cml-foundation.org.